Gilead Sciences (GILD) 10-K Summary — Year Ended Dec 31, 2025
The company reported an increase in total revenue compared with the prior period. Operating income, net income, and operating cash flow each showed strong absolute figures.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
The company reported an increase in total revenue compared with the prior period. Operating income, net income, and operating cash flow each showed strong absolute figures.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$29.4B
Revenue reported for the fiscal year.
Operating income
$10B
Income from operations reported for the year.
Net income
$8.5B
Net income reported for the year.
Operating cash flow
$10B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $27.3B | -0.1% |
| Dec 31, 2023 | $27.1B | -0.6% |
| Dec 31, 2024 | $28.8B | +6.0% |
| Dec 31, 2025 | $29.4B | +2.4% |
Business overview
Gilead Sciences is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies in areas such as virology, oncology, and inflammation. The business overview references a discussion of the company's operations and market position, while the risk factors and cybersecurity sections provide additional context on the operating environment.
Financial performance
Revenue for the period increased compared to the same period a year earlier. Operating income and net income both remained at high levels, and cash generated from operations was substantial.
Material risks
The filing identifies risk factors including those associated with the company's business operations, regulatory environment, and cybersecurity. These risks are detailed in the risk factors section and may affect future performance.
Liquidity and capital
The liquidity and capital resources section discusses the company's financial condition and sources of funding. No specific capital allocation themes beyond general operational needs are explicitly detailed in the supplied context.
What to watch
Readers should monitor the trajectory of revenue growth and whether it accelerates or decelerates in subsequent filings.